The effectiveness of methylphenidate in the management of Attention Deficit Hyperactivity Disorder (ADHD) in people with intellectual disabilities: A systematic review.
Methylphenidate helps just half of kids with ID+ADHD and brings clear side effects—measure behavior closely if you trial it.
01Research in Context
What this study did
Tarrant et al. (2018) looked at 13 past drug trials. All trials tested methylphenidate versus placebo in youth who had both intellectual disability and ADHD.
The team asked: does the pill still curb ADHD symptoms when ID is also present?
What they found
About four in ten kids showed clear ADHD improvement. This rate is lower than the usual six or seven in ten seen in typically developing children.
Sleep loss, appetite drop, and irritability were common side effects.
How this fits with other research
Johnson et al. (1994) ran one of the very trials Nick later counted. R’s team saw medication lift on-task behavior for two of three children, matching the modest benefit Nick found.
Heavey et al. (2000) warned that most 1990s drug studies in ID were weak. Nick’s stricter 2018 review keeps that caution alive: evidence remains thin.
Taylor et al. (2017) showed behavioral sleep plans fix insomnia in ID without drugs. Nick lists sleep trouble as a methylphenidate side effect. The two reviews together hint: try behavior first for sleep, then weigh stimulant risks.
Why it matters
You may see families hoping for a quick pill fix. Share Nick’s numbers: only a fifty-fifty shot at success, plus appetite and sleep costs. Start a brief data sheet on ADHD targets before prescribing. If you trial methylphenidate, schedule a two-week side-effect check and keep behavioral teaching in place.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Start a simple daily count of on-task minutes and evening sleep hours before the doctor visit so you have baseline data.
02At a glance
03Original abstract
BACKGROUND: The effectiveness of psychostimulants, primarily methylphenidate (MPH), in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the general population of typically growing children and adolescents is well established through many Randomised Controlled Trials (RCTs). AIMS AND METHODS: We carried out a systematic review of all the RCTs in people with intellectual disabilities (ID) that assessed effectiveness of MPH on the core ADHD symptoms. OUTCOMES AND RESULTS: We included 15 papers from 13 studies that were all on children and adolescents with ID (315 participants were on MPH and placebo respectively), 12 of which used a cross over design, and one used a parallel design. On average around 40-50% responded to MPH in the ID group whereas around 70-80% response rate is reported among the non-ID children. Because of the heterogeneity of the outcome data it was not possible to carry out a meta-analysis. Significant adverse events included sleep difficulties and poor appetite along with weight loss and also irritability, social withdrawal and increased motor activities including tic. CONCLUSIONS AND IMPLEMENTATION: On the basis of the poor quality evidence that is available, it seems that MPH may be effective in some but not all children and adolescents with ID and ADHD.
Research in developmental disabilities, 2018 · doi:10.1016/j.ridd.2018.08.017